News

Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings

IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.

Yahoo·07:19IDXX

IDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth?

Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on IDXX. IDEXX Laboratories, Inc.’s share was trading at $553.48 as of October 21st 2026. IDXX’s trailing and forward P/E were 36.65 and 31.45 respectively […]

Yahoo·16:18IDXX

Goldman Sachs Sees a Shift in the Stock Market — and Names 2 Stocks to Buy Now

Long-term stock market performance depends on more than economic growth, interest rates, and corporate earnings. Broader trends that develop over many years can also create investment opportunities, particularly for companies positioned to benefit from lasting changes in consumer behavior and business spending. These trends may become especially important as the pace of economic growth slows. With investors facing a more challenging environment, Goldman Sachs Chief U.S. Equity Strategist Ben Sni

Yahoo·13:48

How Unusual Is Zoetis's Latest Sales Growth?

For questions about this article or underlying research, email help@trefis.com.

Yahoo·23:34

IDEXX Laboratories (IDXX) Rebounds On Jefferies Support, Is It Still 20% Undervalued?

IDEXX Laboratories (IDXX) drew fresh attention after Jefferies reiterated its Buy rating while cutting two animal health peers on pricing concerns, and highlighted diagnostics as relatively better insulated within the broader veterinary and livestock market. Recent trading has shifted in IDEXX Laboratories' favor, with a 7 day share price return of 5.47% and a 30 day share price gain of 8.27%. However, the year to date share price return is down 16.73% and the 1 year total shareholder return...

Yahoo·01:18IDXX

Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo·11:10IDXX

Jefferies downgrades Zoetis, Elanco on pricing risk; prefers IDEXX

Investing.com -- Jefferies downgraded Zoetis and Elanco to Hold from Buy on Tuesday, warning that pricing power in animal health is at risk. The firm reiterated its Buy rating on IDEXX Laboratories.

Yahoo·09:06IDXX

Idexx (IDXX) Moves to Buy: Rationale Behind the Upgrade

Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo·11:00IDXX

JP Morgan Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $750

JP Morgan analyst Chris Schott maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $775 to $750.

Benzinga·07:55IDXX

IDEXX Laboratories’ Q3 2026 Earnings: What to Expect

IDEXX Laboratories is set to report its Q3 results next month, with analysts expecting single-digit year-over-year EPS growth.

Yahoo·08:51IDXX

Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls

Spotify upgraded, Alibaba initiated: Wall Street's top analyst calls

Yahoo·09:41

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating.

Benzinga·03:54IDXX

Keybanc Initiates Coverage On IDEXX Laboratories with Sector Weight Rating

Keybanc analyst Steve Dechert initiates coverage on IDEXX Laboratories (NASDAQ:IDXX) with a Sector Weight rating.

Benzinga·

IDEXX Laboratories to Release 2026 Third Quarter Financial Results

WESTBROOK, Maine, October 01, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.

Yahoo·11:30IDXX

Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories

Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX). Financial terms were not disclosed.

Yahoo·09:00IDXX

Should You Continue to Hold IDXX Stock in Your Portfolio?

IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.

Yahoo·08:53IDXX

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure

Yahoo·11:02IDXX

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of

Yahoo·10:02IDXX

IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics

On September 16, IDEXX Laboratories (NASDAQ:IDXX) announced it had bought CoVetAI, a fast-growing veterinary software company whose tool listens during appointments and organizes what gets said and done. It sounds like a productivity gadget. But IDEXX is pitching it as a way to put the right patient details in front of a vet at the […]

Yahoo·16:17IDXX

IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide

IDEXX Laboratories has seen a mixed share price story in recent years, and the question now is whether its current US$506.48 level lines up with the cash flows the business may generate over time. Recent price pressure and fresh AI-driven software ambitions are pulling investor attention back to a simple issue: what are those cash flows worth today? Over the past 5 years the stock has delivered a decline of 25.8%, which puts the focus squarely on whether the cash flow outlook still supports...

Yahoo·23:15IDXX

IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus

IDEXX Laboratories (IDXX) drew fresh attention after expanding its Faecal Dx antigen testing platform in the United Kingdom to cover taeniid tapeworms, including Taenia and Echinococcus species, during routine veterinary visits. Recent moves by IDEXX Laboratories, including the Faecal Dx expansion and the CoVetAI acquisition, come as the share price sits at US$506.48. The year-to-date share price return is down 24.4%, but the 3-year total shareholder return remains positive at 15.46%,...

Yahoo·18:16

IDEXX Stock Gains Following the Acquisition of CoVet

IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.

Yahoo·09:08IDXX

Is IDEXX’s Expanded Zoonosis Testing Menu Altering The Investment Case For IDEXX Laboratories (IDXX)?

IDEXX Laboratories recently expanded its Faecal Dx antigen testing platform in the United Kingdom to include taeniid tapeworm detection, broadening routine intestinal parasite screening to seven clinically relevant parasite groups and triggering automatic, complimentary Echinococcus RealPCR follow-up tests for positive cases. This expansion deepens the clinical scope and perceived value of Faecal Dx, which has already been used in more than 50 million tests globally since 2012, potentially...

Yahoo·07:11IDXX

IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection

WESTBROOK, Maine, September 17, 2026--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.

Yahoo·03:00IDXX

IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).

Yahoo·15:00IDXX

Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?

IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish outlook on its prospects.

Yahoo·09:09IDXX

Insider Decision: Andrew Emerson Exercises Options At IDEXX Laboratories For $101K

In a new SEC filing on August 24, it was revealed that Emerson, EVP at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S. Securities

Benzinga·07:01IDXX

Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?

IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.

Yahoo·10:54IDXX

Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]

Yahoo·12:42IDXX

IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

Yahoo·12:37IDXX

Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?

IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

Yahoo·11:08IDXX

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day August 13, 2026 8:00 AM EDTCompany ParticipantsMichael Erickson - CEO, President & DirectorJulie...

SeekingAlpha·13:41IDXX

IDEXX Labs Executing, But Valuation Continues To Weigh On That Execution

SeekingAlpha·01:24IDXX

IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests

IDEXX Laboratories (NASDAQ:IDXX) outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to incre

Yahoo·15:03IDXX

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow

2026-08-14. The following slide deck was published by IDEXX Laboratories, Inc.

SeekingAlpha·09:34IDXX

Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?

IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...

Yahoo·22:10IDXX

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.

Yahoo·12:28IDXX

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

WESTBROOK, Maine, August 11, 2026--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

Yahoo·07:00IDXX

Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710

Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.

Benzinga·05:51IDXX

IDEXX Laboratories: Worth The Premium

IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.

SeekingAlpha·04:00IDXX

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

Yahoo·12:45IDXX

UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.

Benzinga·12:27IDXX

Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.

Benzinga·10:58IDXX